744081
Last Update Posted: 2023-03-10
Recruiting has ended
All Genders accepted | 18 Years + |
130 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
Eligibility
Relevant conditions:
AML
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov